button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus interferon alpha
Ipilimumab (10 mg/kg) vs. interferon alpha 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		-NaN [NaN; NaN] /10000
0/0 vs. 0/0
ipilimumab alone vs. interferon alpha 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		-NaN [NaN; NaN] /10000
0/0 vs. 0/0
versus Ipilimumab (10 mg/kg)
nivolumab alone vs. Ipilimumab (10 mg/kg) 1 -243 [-793; 307] /10000
100/453 vs. 111/453		--1148 [-1781; -515] /10000
154/453 vs. 206/453
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 ---3254 [-4961; -1546] /10000
15/56 vs. 35/59
versus placebo
Ipilimumab (10 mg/kg) vs. placebo 1 -1085 [-1703; -468] /10000
162/475 vs. 214/476		--1250 [-1877; -623] /10000
234/475 vs. 294/476
nivolumab alone vs. placebo 1 ---2145 [-3794; -496] /10000
35/59 vs. 42/52
nivolumab plus ipilimumab vs. placebo 1 ---5398 [-6977; -3819] /10000
15/56 vs. 42/52
pembrolizumab alone vs. placebo 1 ---1651 [-2226; -1075] /10000
135/514 vs. 216/505

mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive

versus placebo
pembrolizumab alone vs. placebo 1 ---1758 [-2376; -1140] /10000
102/428 vs. 176/425

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab alone vs. ipilimumab alone 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		-1123 [-1891; -355] /10000
119/316 vs. 154/315		-
nivolumab plus ipilimumab vs. ipilimumab alone 2 NaN [NaN; NaN] /10000
0/0 vs. 0/0		-2409 [-3048; -1769] /10000
80/409 vs. 158/362		-
versus ipilimumab followed by nivolumab
nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab 1 -2185 [-3808; -562] /10000
24/68 vs. 40/70		--
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		167 [-366; 701] /10000
45/314 vs. 40/316		-
relatlimab plus nivolumab vs. nivolumab alone 1 -NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
versus Standard of Care (SoC)
tremelimumab vs. Standard of Care (SoC) 1 -361 [-960; 239] /10000
260/328 vs. 271/327		--

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 1217 [-2442; 4876] /10000
12/23 vs. 4/10		-1783 [-5280; 1715] /10000
12/23 vs. 7/10		-
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 -708 [-1553; 136] /10000
93/256 vs. 112/258		-1157 [-1983; -331] /10000
148/256 vs. 179/258		-

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus dacarbazine
nivolumab alone vs. dacarbazine 1 -2234 [-3124; -1345] /10000
50/210 vs. 96/208		-2694 [-3571; -1816] /10000
108/210 vs. 163/208		-
versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 --2590 [-4480; -700] /10000
30/72 vs. 25/37		-
versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone 1 152 [-583; 888] /10000
45/222 vs. 42/224		450 [-476; 1377] /10000
121/222 vs. 112/224		-

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus gp100
ipilimumab alone vs. gp100 1 -1451 [-2379; -522] /10000
100/137 vs. 119/136		--
ipilimumab plus gp100 vs. gp100 1 -1157 [-1852; -462] /10000
306/403 vs. 119/136		--
versus ipilimumab alone
Ipilimumab (10 mg/kg) vs. ipilimumab alone 1 -529 [-1162; 104] /10000
262/365 vs. 279/362		-130 [-556; 296] /10000
328/365 vs. 330/362		-
ipilimumab plus gp100 vs. ipilimumab alone 1 294 [-559; 1146] /10000
306/403 vs. 100/137		--
pembrolizumab (10mg/kg) vs. ipilimumab alone 1 -812 [-1640; 16] /10000
119/277 vs. 142/278		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone 1 -735 [-1562; 92] /10000
122/279 vs. 142/278		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
versus placebo plus SoC
ipilimumab plus SoC vs. placebo plus SoC 1 -811 [-1473; -149] /10000
196/250 vs. 218/252		-729 [-1354; -105] /10000
203/250 vs. 223/252		-
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC) 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
pembrolizumab (10mg/kg) vs. Standard of Care (SoC) 1 -687 [-1647; 274] /10000
117/181 vs. 128/179		-1698 [-2533; -862] /10000
126/181 vs. 155/179		-
pembrolizumab (2mg/kg) vs. Standard of Care (SoC) 1 -318 [-1266; 631] /10000
123/180 vs. 128/179		-1493 [-2319; -666] /10000
129/180 vs. 155/179		-

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 -833 [-2543; 876] /10000
19/60 vs. 24/60		-1667 [-3394; 61] /10000
31/60 vs. 41/60		-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons